Disease · EFO_0008585

ST Elevation Myocardial Infarction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ST Elevation Myocardial Infarction. Diseases, record EFO_0008585. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008585

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ST Elevation Myocardial Infarction; Open Targets
Open Targets ID: EFO_0008585; Open Targets
Other names: ST Elevation Myocardial Infarction by ECG Finding, ST Elevation Myocardial Infarction by EKG Finding, STEMI; Open Targets
NCI Thesaurus: C101888; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 38 drugs, from DailyMed; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RETEPLASE	CHEMBL2107885	Enzyme	Approval	DailyMed	1	0	0	Drugs and targets
TICAGRELOR	CHEMBL398435	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PRASUGREL	CHEMBL1201772	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TENECTEPLASE	CHEMBL2108791	Enzyme	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
ZALUNFIBAN	CHEMBL3114577	Small molecule	Phase 3	ClinicalTrials.gov	2	1	1	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets49

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
P2RY12	P2Y purinoceptor 12	4	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/64805	Drugs and targets
ITGA2B	Integrin alpha-IIb/beta-3	3	Integrin alpha-IIb/beta-3 inhibitor	Phase 3	https://conductscience.org/library/genes/3674	Drugs and targets
ITGB3	Integrin alpha-IIb/beta-3	3	Integrin alpha-IIb/beta-3 inhibitor; Integrin alpha-V/beta-3 inhibitor	Phase 3	https://conductscience.org/library/genes/3690	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
INSR	Insulin receptor	2	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
PCSK9	PCSK9 mRNA	2	PCSK9 mRNA RNAi inhibitor; Subtilisin/kexin type 9 inhibitor	Phase 3	https://conductscience.org/library/genes/255738	Drugs and targets
PLAT	Tissue-type plasminogen activator	2	Tissue-type plasminogen activator exogenous protein	Approval	https://conductscience.org/library/genes/5327	Drugs and targets
CD14	Monocyte differentiation antigen CD14	1	Monocyte differentiation antigen CD14 inhibitor	Phase 1/2	https://conductscience.org/library/genes/929	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
CXCR4	C-X-C chemokine receptor type 4	1	C-X-C chemokine receptor type 4 antagonist	Phase 2	https://conductscience.org/library/genes/7852	Drugs and targets

1 to 10 of 49

See all 49 targets

Trials39

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03317002	AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).	Phase 2	129	2021-06-30	Coronary Artery Disease	ATULIFLAPON	Its record names the disease	ClinicalTrials.gov
NCT02081443	In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients	Not applicable	60	2017-03-03	Coronary Artery Disease	CANGRELOR, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT01898442	High Ticagrelor Loading Dose in STEMI	Phase 2	52	2015-06-08	Coronary Artery Disease	TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00670228	Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction	Phase 3	34	2011-02-11	AMI	INSULIN GLARGINE, INSULIN GLULISINE	Its record names the disease	ClinicalTrials.gov
NCT04825743	A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI	Phase 3	2,463		ST-elevation Myocardial Infarction (STEMI)	ZALUNFIBAN	Its record names the disease	ClinicalTrials.gov
NCT06318481	TADCLOT- a Double Blind Randomized Controlled Trial	Phase 3	2,200		Stent Thrombosis, Myocardial Infarction, Acute	CLOPIDOGREL, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT01997294	Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction	Not applicable	1,200		Acute Myocardial Infarction	ATORVASTATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00785954	Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]	Phase 2	1,180		Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes	DELCASERTIB	Its record names the disease	ClinicalTrials.gov
NCT05329155	Early Administration of Heparin At FMC for PPCI of STEMI Patients	Not applicable	1,145		STEMI, Primary PCI	HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT02934217	Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study	Phase 3	868		ST Elevation Acute Myocardial Infarction	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 39

See all 39 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ticagrelor 180mg vs Ticagrelor 90mg: serious adverse events	0 of 30	0 of 30	60	NCT02081443	Trial comparisons
Intensive Insulin Therapy (IIT) vs Standard Glycemic Care (SGC): serious adverse events	6 of 16	3 of 13	29	NCT00670228	Trial comparisons

Papers from its trials41

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26304941	RESULT	1	PubMed
24485867	RESULT	1	PubMed
23063476	RESULT	1	PubMed
23047939	RESULT	1	PubMed
22406244	RESULT	1	PubMed
21981277	RESULT	1	PubMed
20417240	RESULT	1	PubMed
20012748	RESULT	1	PubMed
19858734	RESULT	1	PubMed
19426242	RESULT	1	PubMed

1 to 10 of 41

See all 41 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008585

GET https://conductscience.org/api/diseases/v1/EFO_0008585/drugs?page=2

API reference For AI assistants